• Healthy Living
Cloning stem cells: What does it mean?
Cloning stem cells: What does it mean?

Creating an embryo just from an egg and a skin cell seems like …

5 ways to handle chronic pain
5 ways to handle chronic pain

While pain medications play an important role in the treatment …

Mediterranean diet is brain food
Mediterranean diet is brain food

Researchers found that study participants who were on a …

France: Drugmaker on trial, suspected in deaths
French drugmaker suspected in deaths

The makers of a diabetes and weight loss drug suspected in the …

Health group didn't disclose HIV tests, apologizes
Health group didn't disclose HIV tests

Kaiser Permanente Northwest is apologizing to nearly 6,500 …

Advertisement

Lilly drug chosen for Alzheimer's prevention study

Drug shows promise for milder forms of disease

Updated: Friday, 18 Jan 2013, 4:17 PM EST
Published : Friday, 18 Jan 2013, 4:17 PM EST

(AP) - Researchers have chosen an experimental drug by Eli Lilly & Co. for a large federally funded study testing whether it's possible to prevent Alzheimer's disease in older people at high risk of developing it.

The drug, called solanezumab, is designed to bind to and help clear the sticky deposits that clog patients' brains.

Earlier studies found it did not help people with moderate to severe Alzheimer's but it showed some promise against milder disease. Researchers think it might work better if given before symptoms start.

"The hope is we can catch people before they decline," which can come 10 years or more after plaques first show up in the brain, said Dr. Reisa Sperling, director of the Alzheimer's center at Brigham and Women's Hospital in Boston.

She will help lead the new study, which will involve 1,000 people ages 70 to 85 whose brain scans show plaque buildup but who do not yet have any symptoms of dementia. They will get monthly infusions of solanezumab or a dummy drug for three years. The main goal will be slowing the rate of cognitive decline. The study will be done at 50 sites in the U.S. and possibly more in Canada, Australia and Europe, Sperling said.

In October, researchers said combined results from two studies of solanezumab suggested it might modestly slow mental decline, especially in patients with mild disease. Taken separately, the studies missed their main goals of significantly slowing the mind-robbing disease or improving activities of daily living.

Those results were not considered good enough to win the drug approval. So in December, Lilly said it would start another large study of it this year to try to confirm the hopeful results seen patients with mild disease. That is separate from the federal study Sperling will head.

About 35 million people worldwide have dementia, and Alzheimer's is the most common type. In the U.S., about 5 million have Alzheimer's. Current medicines such as Aricept and Namenda just temporarily ease symptoms. There is no known cure.

Online:

Alzheimer's info: http://www.alzheimers.gov

Alzheimer's Association: http://www.alz.org

  • Comments
With WDTN.com's new commenting system you don't need to register. You can login with an existing Facebook, Yahoo!, Google, or Twitter account and more.
 

blog comments powered by Disqus

News Link Icon See the latest county jail bookings»

Advertisement
  • Mugshot Gallery

Mugshot Gallery

The following people have recently been booked into Jail. They may not have been convicted of the crimes they are charged with and are innocent until proven guilty.

See gallery »

Advertisement

Advertisement